Introduction {#s1}
============

Adipose dysregulation is fundamental to several important human disease states, such as obesity, chronic lymphedema and lipedema. In contrast to the unwanted effects of excess adipose tissue accumulation, however, adipose tissue also plays a critical physiological role ([@B72]; [@B186]). In humans, fat performs key functions, including energy storage and metabolism, thermoregulation, shock absorption and hormone metabolism ([@B170]; [@B248]). In addition, clinical use of fat tissue has revealed important potential therapeutic applications for adipose tissues in the treatment of human disease ([@B170]; [@B248]). Whilst the clinical use of fat initially began as a physical 'space filler' or 'contour correction' technique, it was through serendipitous observation of the tissues being filled with fat, that an even more important role has emerged -- the role of adipose tissue as a putative therapeutic ([@B157]).

An adipose derived stem cell (ADSC) is defined as a mesenchymal cell within adipose tissue with multipotent differentiation and self-renewal capacity. Adult stem cells have found an important role in tissue engineering and regenerative medicine, as they may be used to develop novel treatment approaches ([@B186]). In particular, ADSCs are a most promising cell type for translational potential and for cell-based regenerative therapies, as they provide a new and unique source for multipotent stem cells that boasts ease and reproducibility of isolation using minimally invasive techniques with low morbidity. As multipotent ADSCs can differentiate into various cell types of the tri-germ lineages, including osteocytes, adipocytes, neural cells, vascular endothelial cells, cardiomyocytes, pancreatic β-cells, and hepatocytes; the use of fat/ADSCs and their cell products represents a paradigm of tissue regeneration and cell restoration.

Here, we review the treatment of human diseases using adipose tissue from its origins as the humble fat graft, through attempts to enrich the concentration of ADSCs within the grafts; to selective attempts to harness the potential paracrine effects of the ADSC secretome, and finally to the most recent evolution -- the targeted use of ADSC exosomes (now known as EVs). We provide a review of the field to date, exploring the therapeutic application of ADSCs and small EVs as delivery vehicles of the ADSC secretome for clinical use in disease. As the focus of the review is ADSC cell products, previous theories of fat differentiating or homing in to replace tissue as 'building blocks', are not extensively addressed.

Fat Grafting, the Stromal Vascular Fraction and ADSCs {#s1_1}
-----------------------------------------------------

### Fat Embryology, Anatomy and Physiology {#s1_1_1}

Adipocytes that form adipose tissue arise from perivascular adipoblast stem cells in the third month of gestation ([@B157]) *via* adipocyte precursors, which, in turn, differentiate into mature fat cells ([@B110]). After adolescence, minimal new adipocytes are formed, and the role of fat cell replication, is thereafter undertaken by post-adipocytes. The ultimate number of fat cells formed is genetically determined, and slightly influenced by environment and nutrition ([@B72]).

Within adipose tissue, lipid droplets may be uni- or multi-loculated ([@B72]). Unilocular signet-ring shaped fat cells (25-200 µm diameter) are characteristic of 'white' fat. Multilocular cells, typically found in so-called 'brown**' or 'beige'** fat, consist of numerous smaller (60 µm) fat droplets ([@B110]). Brown fat occurs in smaller quantities near the thymus and in dorsal midline region of the thorax, neck and abdomen ([@B167]; [@B72]) and plays a role in regulating body temperature *via* non-shivering thermogenesis, a mitochondrial mechanism of heat generation *via* a specific carrier called an uncoupling protein ([@B47]; [@B110]). In contrast, white fat performs three distinct functions of heat insulation, mechanical cushioning, and an energy source/storage sync; ([@B99]; [@B110]). Fat for clinical therapeutic use is sourced predominantly from areas of white fat.

Adipocytes have two different catecholamines receptors (lipolytic β -1 receptors that secrete lipase and α -2 receptors which block lipolysis) ([@B110]). During weight gain, fat deposition occurs throughout the subcutaneous and visceral areas relatively evenly ([@B110]), into existing adipocytes (hypertrophic growth) ([@B72]). In contrast, when a patient is greater than thirty percent above the ideal weight (body mass index (BMI) over thirty-five), new fat cells are produced (hyperplastic obesity) ([@B72]). Hyperplastic cells are more resistant to dieting and exercise ([@B211]). During weight loss, visceral fat is preferential lost, due to greater sensitivity to lipolytic stimulation signals ([@B110]). This a process associated with improved insulin resistance ([@B198]). Bariatric surgery reduces both visceral and subcutaneous fat, leading to overall improved metabolic profiles ([@B186]), however surgery to remove subcutaneous fat (liposuction or abdominoplasty) do not lead to improved metabolic profiles ([@B198]). The largest amount of visceral fat occurs at level of umbilicus and the greatest amount of subcutaneous fat is found in the region of the buttocks; however, these distributions may vary significantly with gender ([@B162]). The abdomen and buttocks are the most commonly used areas for fat harvest for fat graft surgery ([@B198]).

### The History and Evolution of Fat Grafting {#s1_1_2}

An autologous graft is defined as the transfer of a tissue(s) to a distant area of the body, without its original blood supply ([@B170]) ([**Figure 1A**](#f1){ref-type="fig"}). In order to survive, therefore, a fat graft needs to gain nutrients and a blood supply and from the native tissue bed into which it has been introduced. It needs early revascularization to avoid death of the grafted tissue ([@B170]; [@B248]). Unfortunately, due to poor graft re-vascularization, cell apoptosis or fat cell necrosis, up to 50%--100% of the initial injected volume may fail to engraft and become resorbed ([@B157]).

![Liposuction, fat grafting and the components of adipose tissue. Schematic diagram depicting **(A)** fat grafting after liposuction of subcutaneous fat from an abdominal donor site. The components of lipoaspirate **(B)** separate into layers of oil (discarded), aspirated adipose tissue and infranatant (composed of blood, plasma, and local anesthetic). The components of adipose tissue and the key constituents of the stromal vascular fraction (SVF) pellet **(C)** may be re-introduced to enhance the fat graft. Further processing of this adipose tissue with collagenase digestion and centrifugation allows the isolation of a SVF pellet. Figure adapted from Shukla et al. (2015) under the CC-BY license ([@B204]).](fphar-11-00158-g001){#f1}

Fat graft surgery was first performed by [@B167], then expanded to breast reconstruction when a lipoma (benign fatty lesion) was transferred from the back to reconstruct a breast after cancer surgery ([@B47]). By the 1980s, early rates of graft take \[(approximately 50% ([@B99])\] had failed to significantly improved, despite multiple technical refinements in graft harvest, centrifuge or infiltration ([@B26]). Irrespective of these loss rates, liposuction techniques using syringe harvest enhanced the popularity of fat grafting for correcting facial contour defects in the 1980s ([@B196]) and led to the introduction of fat grafting for the correction of soft tissue deficits in other body areas ([@B40]; [@B246]; [@B211]; [@B198]) ([**Figures 1A, B**](#f1){ref-type="fig"}). Nevertheless, significant numbers of patients who underwent fat grafting continued to suffer graft loss, and those in whom graft take was achieved endured up to 70% loss of volume ([@B157]; [@B162]).

More recently, fat grafting has been used in staged breast reconstruction following oncological mastectomy, and has been adapted in some settings, to a single-stage, large volume injection procedure ([@B119]). Various authors have suggested differing methods of injection for achieving optimal graft take, ranging from individual droplet deposits (the so-called pearling technique) to a multilayered and multidirectional lattice configuration as an adaptation to the pre-existing standard 3 mm linear graft injections techniques ([@B40]).

Overall, no consensus had been reached regarding the optimal technical procedure to maximize graft take. Whilst the nuances have been debated, the basic principle is that adipose tissues are removed from beneath the skin *via* minimal-access incisions using a hollow, blunt-ended but perforated steel surgical tube, attached to a source of external suction and collection reservoir.

### Principles of Fat Grafting, Graft Enhancement and Treatment With ADSCs {#s1_1_3}

Several technical modifications have been described to enhance fat graft reliability. It has been suggested that graft survival occurs through imbibition then angiogenesis ([@B120]) from surrounding tissues, promoted through hypoxic-driven protein growth factors. Therefore, various additions such as collagen, FGF, and insulin ([@B94]; [@B9]) were suggested to enhance adipocyte survival; however, did not result in significant graft survival gains. The skin quality overlying areas of fat injection were anecdotally observed to improve, therefore, it was suggested that this may be an influence of stem cells within the introduced adipose cell population ([@B193]). The mesenchymal stem cells (MSCs) thought to be instrumental in these effects were hypothesized to originate from pre-adipocytes (ADSCs) within the stromal vascular fraction (SVF) of liposuction aspirate ([@B76]); or from MSCs derived from blood vessels ([@B60]).

Regardless, of all the different variables in fat grafting, the concept of multipotent stem cells populating fat grafts became the new justification for the use of fat graft. ADSCs became the central focus of enhancing grafts and lately, a potential factor in reversing tissue injury, such as injury occurring in radiotherapy ([@B90]). ADSCs were initially isolated nearly 2 decades ago by Zuk and colleagues ([@B263]). Eto et al. suggested that ADSCs had lower metabolic demands and were more resistant to the mechanical trauma of fat grafting ([@B247]; [@B59]; [@B223]), and were thus more robust compared to adipocytes ([@B263]; [@B227]; [@B203]; [@B150]; [@B221]; [@B209]; [@B181]). Other authors showed enhance graft survival rates due to greater levels of angiogenesis (via either imported endothelial progenitor cells or ADSCs) generating neo-vasculature ([@B217]; [@B258]; [@B128]). Butala et al. on the other hand, postulated that ADSCs in a graft may themselves chemotactically recruit further stem cells, particularly from bone marrow, or differentiate into fat cells themselves ([@B258]; [@B21]; [@B128]).

To enhance the abundance of ADSCs within fat grafts ([@B23]; [@B59]; [@B128]; [@B229]) Yoshimura et al. proposed "cell-assisted lipotransfer enrichment" in which the surplus lipoaspirate was separated into components by centrifugation and the lipoaspirate supplemented with additional SVF ([@B157]; [@B69]; [@B246]; [@B248]; [@B89]; [@B194]; [@B129]). Briefly, SVF \[comprised of 10% ADSCs ([@B260]; [@B211]; [@B3])\] is derived from a lipoaspirate component that is surplus to the volume needed to fill a particular soft-tissue deficit ([@B198]). Subsequent to digestion with collagenase, centrifugation creates an SVF pellet ([**Figure 1C**](#f1){ref-type="fig"}). Eventually, the SVF pellet is introduced to the lipoaspirate, in readiness for injection with the ADSCs as part of a fat graft ([@B263]; [@B120]; [@B162]; [@B247]; [@B248]; [@B221]; [@B223]; [@B95]). A randomized control trial was designed by Kolle et al. to assess enrichment of lipoaspirate with ADSC concentrations of up to 2,000 times over physiological levels ([@B122]). Quantification using magnetic resonance scans suggested that ADSC-enriched groups yielded higher graft retention volumes ([@B23]; [@B128]).

Collectively, this work implied that enrichment of fat grafts could increase viability, volume retention, and neo-vascularization, whilst reducing necrosis rates. The findings also supported the theory that adding ADSCs may augment fat graft survival by bolstering adipogenesis, the supporting vasculature and/or diminishing cell apoptosis---key features of the regenerative properties of fat graft ([@B180]; [@B258]; [@B41]; [@B128]).

### Characteristics of ADSCs {#s1_1_4}

ADSCs are defined as plastic-adherent cells (in standard culture conditions) ([@B56]; [@B261]), cells exhibiting a CD34^+^, CD31^-^, and CD45^-^ cell surface marker profile ([@B86]; [@B201]; [@B245]; [@B115]; [@B228]; [@B143]; [@B261]; [@B2]; [@B7]; [@B10]; [@B265]) and cells showing differentiation multi-potency into mature bone, cartilage, and fat ([@B264]).

In adults, stem cells may uniquely differentiate into more specialized cell types to: i) replenish injured cells, ii) preserve tissue integrity, iii) maintain cell homeostasis during normal growth or healing ([@B23]; [@B122]). Therefore, MSCs show promising utility in tissue regeneration ([@B57]; [@B89]; [@B17]; [@B240]; [@B67]; [@B129]; [@B249]). As is the case in bone marrow derived MSCs, ADSCs are may undergo differentiation into a variety of distinct mature tissue types including fat, cartilage, bone, skin, muscle, endothelial, and nerve-like cells when grown with a particular set of induction factors ([@B263]; [@B162]; [@B57]; [@B221]). ADSCs also boast the additional benefits that the stem cell yield from fat is 500-fold greater than that obtained from bone marrow ([@B69])---\[5x10^5^ ADSCs can be derived from 400-600g of fat ([@B260]; [@B153])\]; and that ADSCs easier and less invasive to harvest overall ([@B198]; [@B204]).

In terms of the cellular secretory profile, ADSCs produce a more extensive range of chemokines, cytokines and protein growth factors ([@B23]; [@B56]; [@B120]; [@B146]; [@B18]; [@B24]; [@B27]; [@B95]; [@B208]). This secretome profile has contributed the understanding that, in contrast to previously held theories that ADSCs would differentiate to actually replace damaged cells (the "building block" or "host replacement" theories ([@B168]; [@B245]; [@B122]; [@B265]; [@B198]); the paracrine effects of the secretome are now considered as more likely to orchestrate the events needed tissue regeneration ([@B180]). The distinct makeup of the ADSCs secretome suggested that ADSCs may influence tissue regeneration by altering the biological and molecular cues driving ([@B86]; [@B122]; [@B10]; [@B41]; [@B67]), angiogenesis ([@B17]; [@B261]; [@B156]; [@B249]) and lymphangiogenesis ([@B143]; [@B240]); while suppressing local immune/inflammatory responses ([@B69]; [@B193]; [@B51]; [@B221]; [@B153]; [@B27]) and reducing fibrogenesis ([@B221]).

Since the time of the initial description of ADSCs, their molecular profile has been the subject of debate ([@B207]; [@B158]). This has been chiefly due to the description of different ADSC purification and culture protocols and differing use of sub-total vs. whole SVF ([@B40]; [@B193]; [@B146]; [@B248]; [@B27]; [@B208]).

### Safety Concerns and Legislative Implementation of Fat Grafting in Clinical Practice {#s1_1_5}

Concerns regarding the use of ADSCs in clinical practice have been three-fold. Firstly, fears arose that introducing stem cells into a former cancer field might encourage recurrent cancer growth due to potential secretion of pro-angiongenic growth factors such as VEGF-A ([@B198]; [@B204]). Secondly, it was hypothesized that chronic calcification occurring in the previously fat grafted areas may make screening/monitoring for the occurrence further cancer difficult ([@B198]; [@B204]). Finally, the addition of components to enhance ADSC efficiency---such as collagenase processing---created the impression that the fat has been significantly altered and therefore ceases to be an autologous tissue transfer, but more a modified therapeutic product ([@B187]). The first of these reservations was addressed when it was contested that, despite *in-vitro* data that suggesting that introducing stem cells might promote cell proliferation, there was no equivalent definitive evidence *in-vivo* to that effect ([@B198]; [@B204]; [@B205]). The second concern was deemed not to be an issue in the hands of an experienced radiologist, who should be expected to differentiate between benign "post-graft" and suspicious calcification ([@B198]; [@B204]; [@B205]). A recommendation of the American Society of Plastic Surgeons against fat grafting for breast reconstruction was dropped in 2009, and subsequent case studies have upheld an acceptable risk profile. ([@B198]; [@B204]; [@B205]). Finally, the addition of processing to fat graft to enhance take rates has rendered the fat graft unusable in some jurisdictions. In Europe, the use of collagenase digestion in fat grafting is considered to be a significant manipulation of the graft and therefore no longer to be homologous ([@B187]). The practical use of manipulative steps is therefore likely to remain a restricted procedure, and would likely need to pass regulatory approval steps akin to those stringent steps required of devices or genetically modified cell treatments.

Functions of ADSCs in Tissue Regeneration {#s1_2}
-----------------------------------------

Since the initial observations made in clinical fat grafting, adipogenic differentiation of ADSCs has been thought to result in restoration of tissue contour and volume. Clinical work indicates that there is new fat near the area of the fat graft introduction, which must have occurred *via* either; i) direct differentiation of introduced ADSC into adipocytes; or ii) ADSCs exerting paracrine effects to influence local stem cells to differentiate into adipocytes ([@B263]; [@B193]; [@B51]; [@B57]; [@B122]; [@B162]; [@B225]; [@B60]; [@B158]; [@B114]). The latter has gained favor of late.

### Differentiation of Transplanted ADSC During Wound Healing {#s1_2_1}

There are several studies demonstrating that transplanted ADSC can potentially promote wound healing by differentiating into specific cell types in animal models of wound healing. For example, Nie et al. showed that intradermally administered ADSCs facilitated wound closure in rats by enhancing re-epithelialization and granulation tissue deposition ([@B169]). The enhanced wound repair in these rats was attributed to differentiation of ADSC into epithelial and endothelial cells, which accelerated cutaneous regeneration and angiogenesis ([@B169]). Kim et al. assessed the efficacy of ADSCs in promoting wound healing introduced *via* three different techniques (topical application, intravenous injection and intramuscular injection) ([@B125]). This study found that mice treated with ADSC exhibited more stratified and differentiated epidermal and dermal layers, with more rapid re-epithelialization and vascularization regardless of the type of ADSC administration compared to control mice ([@B125]). Further, Wu et al. employed an ADSC-seeded silk fibroin chitosan film in a rat incisional cutaneous wound healing model, and showed accelerated wound healing and colocalization of transplanted ADSCs which displayed enhanced levels of endothelial markers CD31 and alpha-smooth muscle actin (α-SMA) ([@B234]). These findings were consistent with another study using an acute radiation ulcer model in rats, in which a portion of transplanted ADSCs were also shown to be colocalized with CD31 ([@B97]). These findings suggest that these ADSCs may have partially differentiated into endothelial cells to promote angiogenesis during wound healing. Lastly, subcutaneously injected ADSCs resulted in a significant increased angiogenesis and enhanced wound healing at 8 weeks post-implantation in rats ([@B132]). Unfortunately, however, these studies failed to directly address the question of whether ADSCs promoted wound healing by differentiating into specific cells types, such as epithelial or endothelial cells, or whether---as the authors claimed---that the increased angiogenesis was due to the ADSC secretomes, including VEGF-A ([@B132]). A limitation of these studies was that they were conducted using tissue immunofluorescence, which relies on optical co-localization of markers that can be more misleading in terms of positive ADSC and CD31 signals, compared to PCR that will tease out distinct cell populations that co-express numerous specific markers. Finally, no differentiation of ADSCs was detected in a rabbit model of wound healing 7 days after topical application, although the animals treated with ADSCs did increase granular tissue formation in the wound area ([@B93]). This finding may suggest that the microenvironment in wounds between rodents and rabbits is critically different, or that ADSC differentiation may not play a significant role as the paracrine secretome of the ADSC population. Further research is required to better understand the differentiating capacity of transplanted ADSC *in vivo*.

### Non-Differentiation Related Mechanisms: Enhancement of Angiogenesis and Lymphangiogenesis {#s1_2_2}

#### Angiogenesis {#s1_2_2_1}

Injection of the ADSCs into the recipient tissue bed is thought to increase perfusion of injured tissues and/or graft viability by: i) paracrine promotion of angiogenesis, or ii) supporting existing vascular structures. The concepts that support the existence of such regenerative mechanisms are based on several key findings regarding fat grafting in murine ischemic injury models ([@B60]). These experiments demonstrated that: i) ADSCs may differentiate into CD31^+^ ECs *in-vivo*; ii) there was enhance density of blood vessels and co-localized fluorescent-labeled ADSCs in or near the vessels; and iii) ADSCs formed a vWF^+^ vessel networks in a Matrigel matrix ([@B114]). Further, the release of angiogenic growth factors by ADSCs has been shown to promote revascularization and wound healing. These included proteins such as IGF, PDGF-bb, FGF, TGF-β, and interleukins IL-6, IL-8, stromal-related proteins MMP inhibitor 1 precursor, MCP-1, ANG, and SDF-1, and vascular-related proteins such as vascular endothelial growth factor (VEGF) -A, -C, and -D, ([@B190]; [@B14]; [@B120]; [@B121]; [@B151]; [@B57]; [@B162]; [@B177]; [@B225]; [@B153]; [@B60]; [@B91]; [@B262]; [@B10]; [@B67]; [@B95]; [@B113]; [@B90]; [@B107]; [@B114]; [@B249]).

#### Lymphangiogenesis {#s1_2_2_2}

ADSCs secrete lymphangiogenic factors that aid in lymphangiogenesis, improving or reversing lymphedema in damaged tissues. Lymphatic fluid stasis was found to result in increased TGF-β1, exerting a hypothesized further anti-lymphangiogenic effect. Blockade of TGF-β1 and ADSC stimulation, in contrast, lead to increased expression levels within ADSCs of lymphatic endothelial cell markers podoplanin and Prox-1 and of lymphangiogenic growth factor VEGF-C. In addition, the protein growth factors detected in ADSCs that differentiate them from other MSCs (VEGF-D, IGF-1, and IL-8) at baseline, all display pro-lymphangiogenic activity ([@B106]; [@B193]; [@B51]; [@B8]; [@B158]; [@B240]).

### Anti-Oxidant, Anti-Inflammatory and Anti-Fibrosis Effects {#s1_2_3}

ADSCs may elicit regenerative benefits by exerting anti-oxidant effects, which in turn provide protective effects combatting cellular injury induced by radical oxygen species, hypoxia, and reperfusion effects following ischemia. Protein growth factors that have been implicated include PDGF-AA, HGF, IL-12, G-CSF, GM-CSF, IGFBPs. Pigmented epithelial derived growth factor, Superoxide dismutase may mediate these effects ([@B31]; [@B121]; [@B122]; [@B91]; [@B28]). Specific ADSC-induced cytokines have also been shown to modulate immune and inflammatory responses, as BMSCs, and ADSCs restrict the proliferation T-cells and B-cells through NFKB-mediated pathways. Further, IL-6 and IL-8 secretion act as attractants for monocytes and macrophages, which also promote wound healing processes ([@B174]; [@B31]; [@B79]; [@B91]; [@B153]; [@B165]; [@B67]; [@B195]; [@B113]; [@B90]; [@B107]).

An additional method of improving epithelialization and wound healing has been shown to be through modulation of granulation tissue formation and of fibrosis. ADSCs co-cultured with fibroblasts *in-vitro* appeared to modify extracellular matrix (ECM) remodeling through down-regulation of gene expression related to production of collagen types I and types III by fibroblasts. Functionally, treatment of keratinocyte and fibroblasts with conditioned media (CM) harvested from ADSC (ADSC^CM^) lead to improved re-epithelialization ([@B13]; [@B68]; [@B164]; [@B174]; [@B82]; [@B77]; [@B79]; [@B137]; [@B91]; [@B165]; [@B138]; [@B195]; [@B251]; [@B28]).

Overall, the endogenous stem cell recruitment along a chemokine gradient to the site of injury or inflammation resulted in improved wound healing, truncation of prolonged inflammatory responses and tissue regeneration ([@B82]). Murine models have demonstrated that MSCs respond by aggregating to a site of tissue damage. Studies tracking systemically introduced human MSCs showed that they home to and became grafted into the site of ischemia or of a necrotic injury. In these studies, SDF1α, produced by ADSCs was the key chemoattractant of other stem cells to the injured area of tissue ([@B13]; [@B68]; [@B164]; [@B54]; [@B82]; [@B77]; [@B209]; [@B59]; [@B251]; [@B28]; [@B70]).

### Implications of Age-Related Changes to Fat Grafting in Clinical Practice {#s1_2_4}

Several clinical applications for adipose-derived stem cell therapy are related to diseases that become more prevalent with age. In studies that examined the changes to the stem cell population, it was found that the differentiation and other functional profiles changes between cells from infanthood, middle age, and elderly donors ([@B108]). Other studies also demonstrated reduced proliferation and migration profile with age, however, this effect was less marked in adipose-derived cells than it was in bone marrow derived stem cell populations ([@B58]). When stem cells were harvested from aged patients and mice, ADSCs were more robust in terms of potential cell yield than was the case with other MSCs, however, in terms of the paracrine signaling and angiogenic potential of stem cells (e.g., in terms of VEGF-A production), there was a marked impairment seen in cells taken from older donors in both *in vivo* and *in vitro* models ([@B58]). Similarly, clonogenic potential in ADSCs was reduced with age and all the effects were linked to a likely telomere shortening and accumulation of reactive oxygen species-related cellular injury ([@B58]). Overall, aging of donor stem cell populations may form an important limitation of the ability of ADSCs to delivery therapeutic benefits that can be derived from younger donor stem cell populations. This limitation may constitute an indication for ADSC function testing prior to clinical use, bolster the case for procedures to enhance ADSC efficacy, or herald the requirement for a delivery system that by-passes the ADSC itself to harness the paracrine secretome and cell products in a more targeted fashion---such as the use of exosomes.

Alternative Approaches to Deliver Beneficial Effects of ADSCs: Small Extracellular Vesicles {#s1_3}
-------------------------------------------------------------------------------------------

### Extracellular Vesicles: Understanding Their Composition {#s1_3_1}

Extracellular vesicles (EVs) are a heterogeneous population of nano- and micro-sized membrane-encapsulated cell particles that are fundamental mediators of intercellular communication. EVs constitute a diverse range of subtypes, namely microvesicles, exosomes, and several other EV populations, classified by The International Society for Extracellular Vesicles (ISEV) ([@B218]). All cell types continuously secrete EVs to the extracellular environment. EVs contain select proteins, peptides, RNA species (microRNAs, mRNAs, and long noncoding RNAs), lipids, and DNA fragments, that act locally or disseminate through circulation to act at specific distal sites to pleiotropically modulate cellular responses *via* paracrine signaling ([@B84]; [@B237]; [@B185]). The origin, nature, morphology, size and content of EVs are diverse and represent a novel signaling paradigm ([@B6]). EV trafficking has been studied extensively in the area of oncology; however, there is now evidence of their seminal roles in intercellular communication in fetal-maternal signaling ([@B61]) and metabolism and tissue regeneration - particularly as trafficking intermediates for adipose tissue ([@B219]). EVs may be divided into distinct classes, each with differing composition, capacity for selective packaging and potential for targeted delivery (and thus potential roles in disease). Comprehensive examination of the composition and molecular function of EVs in physiology and pathophysiology must be explored in the context of individual cell types, in order to facilitate cell-specific functions and therapeutic use \[reviewed in ([@B83])\].

### Defining Extracellular Vesicles {#s1_3_2}

Numerous terminologies have been described to define and identify EVs ([@B80]). Overall, two main classes of EVs exist: large EVs (or shed microvesicles) and small EVs (or exosomes) ([@B42]; [@B226]). Large EVs (\~150--1500 nm) are generated by outward blebbing of specific regions of the plasma membrane ([@B222]; [@B226]; [@B154]). Small EVs (30--150 nm) originate as intraluminal vesicles (ILVs) through the endosomal maturation pathway (i.e., multivesicular bodies (MVBs)), which can release ILVs as exosomes into the extracellular space ([@B188]).

During their biogenesis, EVs are selectively enriched with diverse cellular bioactive cargo molecules. RNAs (coding, non-coding), DNAs (single-/double-stranded), proteins (peptides, fusion proteins), and lipids are selectively incorporated into distinct types of EVs ([@B226]; [@B154]). Further, diverse surface-bound proteins (e.g., receptors, tetraspanins) that are characteristic of the cell of origin, are selectively displayed on secreted EVs and play a crucial role in the recognition of target recipient cells and orchestrating EV localization; as well as uptake by recipient cells ([@B238]).

Although a growing number of studies have investigated the roles of EVs in cell--cell communication, an understanding of specific mechanisms behind their biogenesis and the heterogeneity of EVs and their subtypes remains rudimentary ([@B83]). The heterogeneity of small EVs and the identification of non-vesicular extracellular content has raised concerns as to the content and function of some exosomes ([@B102]). Currently, the extent to which small EVs (and exosomes) differ from other EVs in terms of their biogenesis and functions remains ill-defined; and specific markers that distinguish large from small EVs are the subject of much research ([@B104]; [@B85]; [@B83]; [@B218]; [@B226]; [@B237]; [@B255]; [@B38]; [@B102]). This research includes the characterization of EV classes and their subtypes, imaging and tracking of EVs, mechanisms of cell and tissue targeting and internalization, post-translational and transcriptional regulation of EVs and their cargo, and administration and duration (i.e., transient vs. stable) of functional effects ([@B236]; [@B83]; [@B226]; [@B237]; [@B154]).

### Isolating and Purifying Extracellular Vesicles for Biophysical Studies and Clinical Utility {#s1_3_3}

The majority of rapid/one-step approaches for isolating EVs do not account for the fact that samples may contain a mixture of vesicle classes/subtypes and co-isolated contaminants such as high-molecular weight protein oligomers, RNA granules, and protein-RNA complexes (e.g., high-/low-density lipoproteins, argonaute-2/AGO2) complexes ([@B102]). Varying methodologies for purifying (enriching) EVs and their modified versions exist, including differential (sequential) ultracentrifugation, density-based fractionation, gel permeation chromatography, affinity chromatography using bio-specific reagents (e.g., antibody targets), membrane ultrafiltration using low-centrifugal force, microfluidic devices, and synthetic polymer based precipitation reagents \[for a discussion on application, yield/purity and scalability of these methods, see ([@B236]; [@B141])\]. The choice of which method for EV isolation used depends on the specific research question or proposed use, as outlined below. Further detail of specific guidelines as recommended by ISEV for studies of EVs has been reported elsewhere ([@B218]).

#### Stringent EV Isolation Procedures {#s1_3_3_1}

EVs can be isolated and purified depending on the application. For stringent biochemical analysis \[e.g. define their luminal cargo---RNA/DNA/lipid/protein species and surface-exposed proteins ([@B238])\] or specific functionality, rigorous purification strategies are critical, including immunoaffinity targeting. Antibody targets that have been successfully employed in this process include those directed against A33 ([@B155]), EpCAM ([@B244]; [@B216]), MHC-II antigens ([@B39]; [@B117]), CD45 ([@B43]; [@B161]), CD63 ([@B22]; [@B175]), CD81 ([@B175]), CD9/CD1b/CD1a/CD14 ([@B231]), CD24/SWA11 ([@B199]), and HER2 ([@B126]). Further, targeted EV capture based on bio-specific synthetic peptides ([@B75]) and proteoglycan enrichment ([@B36]; [@B11]) have been described. Other approaches to purify EVs include sequential centrifugal membrane ultrafiltration ([@B235]) and density-based fractionation using differential centrifugation (i.e., top- or bottom-loaded) (e.g., OptiPrep™/iodixanol) ([@B105]; [@B25]; [@B84]; [@B232]).

#### Generation of EVs for Therapeutic Studies {#s1_3_3_2}

By virtue of their bioactive cargo EVs have inherent therapeutic potential ([@B49]; [@B48]; [@B191]). Small EVs from human MSCs have been used in tissue regenerative medicine to reduce infarction size in a mouse model of myocardial ischemia/re-perfusion injury ([@B133]). For these studies, large-scale production of functional homogeneous MSC-derived exosomes was accomplished using size-based fractionation. In another therapeutic application, small EVs from dendritic cells (and tumor cells) have been trialed in vaccine studies ([@B197]; [@B131]; [@B182]; [@B220]). Navabi et al. described a large-scale production method combining ultrafiltration and sucrose/deuterium oxide for generating good manufacturing (GMP) grade small EVs for use in clinical trials ([@B166]).

### Extracellular Vesicle Regulation of Adipose Function {#s1_3_4}

Several key studies have demonstrated the role of EVs in adipose function. Recently, adipose tissue macrophages were shown to release exosomes containing a specific miRNA to facilitate glucose intolerance (from fat mice population) and insulin resistance (in lean mice population) ([@B233]). Exosome-containing miR-155 was shown to transfer into insulin target cell types, regulating cellular insulin response, insulin sensitivity, and glucose homeostasis ([@B233]). The ability of adipose tissue macrophage-derived exosomes to modulate systemic insulin and glucose tolerance *via* different miRNA compositions depended on their adipose phenotype ([@B233]). Thomou et al. further highlighted the contribution of adipose EVs to adipose function, with 653 miRNAs expressed in serum-derived exosomes from non-obese, or non-diabetic mice ([@B219]). Importantly, adipocyte-specific Dicer KO mice were used to deplete adipocyte-derived miRNAs, revealing that exosomes from adipocytes containing miR-99b, inhibited liver FGF21 expression ([@B219]). It was further suggested that these changes in FGF21 facilitated the overall phenotype of the Dicer KO mice. Interestingly, Ying et al. demonstrated that such changes were only marginally affected by adipose tissue macrophages-derived exosomes ([@B233]), indicating that significant differences are present between the miRNA profiles of different cell types within the source adipose tissue. Finally, it was observed that in adipocyte-specific Dicer KO, there was a substantial reduction in circulating exosomal microRNAs ([@B219]).

A seminal study by Flaherty et al. identified that adipocytes communicate with adipose tissue macrophages through EVs ([@B66]). This is achieved by directly transferring lipids to differentiate bone marrow precursors into adipose tissue macrophage-like cells, with critical implications for obesity-associated pathologies ([@B66]). The authors highlighted the fact that adipose tissue from lean mice releases \~1% of its lipid content per day *via* exosomes *ex-vivo*, a rate that more than doubles in obese animals. Amose et al. also showed that EVs in human plasma increased significantly with BMI, supporting a role of EVs as metabolic relays in obesity ([@B5]). This study demonstrated a key role for large EVs in the transfer of macrophage migration inhibitory factor (MIF) and the link between adipose-derived EVs and macrophage regulation.

Further investigating the role of exosomes in adipose tissue, Crewe et al. showed that adipose tissue EVs modulated crosstalk between adipocytes and stromal vascular cells for metabolic signaling and regulation ([@B44]). Quantities of adipose tissue EVs were increased in a fasted state (compared with genetic and diet-induced obesity), partially because of glucagon-stimulated EV secretion from endothelial cells ([@B44]). The authors showed dysregulation of important signaling proteins (antioxidant response, mitochondrial respiration) and lipid species involved in stress response. A critical finding was that extracellular molecules are internalized and packaged into EVs ([@B44]), representing a new mechanism by which blood-borne signals are integrated into and supplied to adipose tissues.

In addition to influencing fat biology, components of the ADSC secretome have also been shown to promote wound healing and neuro-regeneration, making it an exciting focus for discovery of potential therapeutic targets ([@B96]; [@B243]); particularly as engineering-specific EV delivery systems is now a reality ([@B243]).

ADSCs for Therapeutic Application in Human Disease {#s1_4}
--------------------------------------------------

Pre-clinical studies of ADSCs and ADSC-exosomes/EVs are listed in [**Table 1**](#T1){ref-type="table"} and [**Table 2**](#T2){ref-type="table"}, respectively. As the exosome/EV field is far less advanced than the clinical practice of fat grafting, the respective advances in the clinical application of each are considered together.

###### 

Pre-clinical studies of ADSCs.

  Disease model          *In vitro* or *In vivo*    Function                             Key findings with ADSC-CM                                                                                                                                                    Reference
  ---------------------- -------------------------- ------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  Cutaneous wound        *In vitro* and *in vivo*   Wound healing                        Reduced UVB-induced wrinkles in mice. Also, ADSC-CM (conditioned media) inhibited UVB-induced apoptosis and enhanced type I collagen synthesis of human dermal fibroblasts   ([@B122])
  Cutaneous wound        *In vitro*                 Wound healing                        Accelerated collagen deposits in human dermis through up-regulation of fibroblasts TGF-β1                                                                                    ([@B111])
  Cutaneous wound        *In vivo*                  Wound healing                        Promote neovascularization and wound repair by up-regulating *Tgfb-1*, *Fgfb,* & *Vegf* gene expression                                                                      ([@B88])
  Cutaneous wound        *In vitro* and *in vivo*   Wound healing                        Enhanced neovascularization and re-epithelialization of wounds by up-regulating VEGF, HGF an FGF protein expression                                                          ([@B169])
  Cutaneous wound        *In vivo*                  Wound healing                        ADSC + platelet-rich plasma activated Rho GTPase signaling and lead to accelerated wound cell migration & re-epithelialization                                               ([@B256])
  Secondary lymphedema   *In vivo*                  Reduce tail swelling                 Promote VEGF-C-mediated lymphangiogenesis and anti-inflammatory M2 macrophages recruitment                                                                                   ([@B202])
  Radiation injury       *In vitro*                 Lymph-angiogenesis                   Promoted bFGF-mediated lymphangiogenesis in irradiated LECs                                                                                                                  ([@B200])
  Alzheimer's disease    *In vivo*                  Neurogenesis                         Secreted IL-10 and VEGF to reduce Aβ plaques and promote neurogenesis and cognitive functions                                                                                ([@B124])
  Alzheimer's disease    *In vivo*                  Neurogenesis                         Reduce oxidative stress and stimulate neuroblast proliferation to improve cognitive function                                                                                 ([@B241])
  Parkinson's disease    *In vivo*                  Neuroprotection                      Inhibit dopaminergic neuronal cell death and reduce brain mitochondrial damage, restore mitochondrial function                                                               ([@B35])
  Parkinson's disease    *In vivo*                  Neuroprotection                      Improved motor function by increasing BDNF and GFPA                                                                                                                          ([@B15])
  Huntington's disease   *In vivo*                  Neuroprotection                      ADSC-extracts improve rotarod test and reduce mHtt aggregates and striatal atrophy *via* CREB-PGC1α                                                                          ([@B101])
  Huntington's disease   *In vivo*                  Neuroprotection                      Improved rotarod performance and limb clasping, increased survival, protected striatal neurons and decreased mHtt aggregates                                                 ([@B136])
  Acute kidney injury    *In vivo*                  Renal protection                     Attenuate I/R-induced renal damage by suppressing apoptosis and inflammation *via* reduction in levels of pro-apoptotic and pro-inflammatory cytokines                       ([@B254])
  Diabetic nephropathy   *In vivo*                  Renal protection                     Reduce oxidative stress and inflammation by inhibiting p38 MAPK signaling pathway                                                                                            ([@B62])
  Breast cancer          *In vivo*                  Tumor promotor or tumor suppressor   ADSC injected into tumor promote tumor growth, c.f. ADSC injected around tumor inhibits tumor growth                                                                         ([@B100])
  Breast cancer          *In vivo*                  Tumor promotor                       Promoted pulmonary metastases by inhibiting miR-20b & activating c-Kit/MAPK-p38/E2F1 signaling                                                                               ([@B239])

###### 

Pre-clincial studies of ADSC-EVs.

  Disease model                                    *In vitro* or *In vivo*   Function             Key findings                                                                                                                               Reference
  ------------------------------------------------ ------------------------- -------------------- ------------------------------------------------------------------------------------------------------------------------------------------ -----------
  Myocardial I/R injury                            *In vivo*                 Cardio-protection    Reduced oxidative stress-induced necrosis and apoptosis in myocardium                                                                      ([@B46])
  Acute myocardial infarction                      *In vivo*                 Cardio-protection    Reduced cardiac apoptosis, fibrosis & inflammation *via* S1P/SK1/S1PR1 pathway & macrophage M2 polarization                                ([@B52])
  Acute myocardial infarction                      *In vivo*                 Cardio-protection    miR-126-enriched ADSC-exosomes reduced cardiac inflammation & fibrosis, induce microvascular generation & migration                        ([@B152])
  Stroke                                           *In vivo*                 Neuro-protection     miR-126-enriched ADSC-exosomes induced neurogenesis, vasculogenesis & inhibit post-stroke inflammation                                     ([@B74])
  Stroke                                           *In vivo*                 Neuro-protection     miR-181-b-5p-enriched ADSC-exosomes promote angiogenesis of brain microvascular ECs post O~2~-glucose deprivation                          ([@B242])
  Neural injury                                    *In vivo*                 Neuro-protection     Reduced neuro-inflammation by suppressing microglia cells activation by inhibiting NF-κβ and MAPK pathways                                 ([@B64])
  Neural injury                                    *In vivo*                 Neuro-regeneration   Promote axonal regeneration & myelination in atrophied gastrocnemius by stimulating secretion of neurotrophic factors from Schwann cells   ([@B30])
  Alzheimer's disease                              *In vitro*                Neuro-protection     Inhibit formation of Aβ plaques and induce neuronal cells proliferation                                                                    ([@B139])
  Huntington's disease                             *In vitro*                Neuro-protection     Reduce mutant Huntingtin protein aggregates, ameliorated abnormal apoptotic protein levels, & restored mitochondrial function              ([@B140])
  Parkinson's disease                              *In vivo*                 Neuro-protection     Reduce gene expression of GFAP, restore astrocytic injury, and increasing dopamine levels                                                  ([@B160])
  Acute kidney injury and chronic kidney disease   *In vivo*                 Renal protection     Promoted tubular regeneration and inhibit AKI-CKD transition *via* SOX9 activation                                                         ([@B259])
  Acute kidney injury                              *In vivo*                 Renal protection     Combined ADSC + ADSC-exosomes reduce renal inflammation, oxidative stress, apoptosis, fibrosis, & glomerular & tubular damage              ([@B145])
  Diabetic nephropathy                             *In vivo*                 Renal protection     Inhibit podocyte apoptosis and induced podocyte autophagy through miR-486-mediated inhibition of Smad1/mTOR signaling pathway              ([@B109])
  Breast cancer                                    *In vitro*                Tumor promotor       Promote migration/proliferation of MCF7 human breast cancer cells *via* Wnt/β-catenin signaling pathway                                    ([@B144])
  Prostate cancer                                  *In vitro* &*in vivo*     Tumor suppressor     Inhibit tumor growth by activating caspase-3/7 pro-apoptotic miR-145 pathway                                                               ([@B213])
  HCC                                              *In vivo*                 Tumor suppressor     miR-122 enriched ADSC-exosomes increase HCC chemosensitivity & inhibit tumor growth                                                        ([@B149])
  Breast cancer                                    *In vivo*                 Tumor suppressor     miR-379 enriched ADSC-exosomes inhibited tumor growth over 6 weeks                                                                         ([@B172])

### Wound Healing {#s1_4_1}

A wound consists of an area of disrupted tissue integrity, architecture and homeostasis. It may be caused by trauma or by thermal or radiation injury ([@B53]; [@B71]). The process of wound healing involves a series of organized molecular events including inflammation, neo-vascularization, scar tissue formation, and tissue remodeling ([@B87]); processes tightly regulated by specific growth factors, such as TGF-β, FGF, and PDGF ([@B81]). In most injuries, wound repair results in scar formation due to recruitment of collagen secreting fibroblasts to enhance the deposition of collagenous ECM ([@B87]). The beneficial effects of ADSC^CM^ on wound healing have been reported in several pre-clinical studies. For example, reduced proliferative capacity and increased apoptosis seen in UVB-irradiated human dermal fibroblasts were reversed with ADSC^CM^ treatment ([@B123]). Similarly, it was shown that ADSC^CM^ stimulated synthesis of type I collagen by human dermal fibroblasts and reduced UVB-induced wrinkles in mice ([@B123]). Another study demonstrated that the mRNA expression of types I and III collagens were enhanced in human dermal fibroblasts following treatment with ADSC^CM^ ([@B111]).

In addition, animal models have shown promising effects of ADSCs on accelerating wound repair. For example, treatment using artificial dermis as a supportive matrix impregnated with autogenic ADSCs in wounded rats resulted in increased vascularization and healing, which was mediated by increased gene expression of genes involved in tissue repair or angiogenesis \[e.g., *Tgfb-1* and *-3*, *Fgfb* and *Vegf* ([@B88])\]. Also in rats, Nie et al. employed an excisional wound healing model and demonstrated that ADSCs secreted pro-angiogenic mediators both *in vitro* and *in vivo* (e.g., VEGF-A, HGF, and FGF), in-turn promoting neo-vascularization and re-epithelial regeneration of wounds, thus accelerating the wound repair ([@B169]). Further, the wound healing effects of ADSCs in skin seems to be augmented when administered in combination with platelet-rich plasma containing several different protein growth factors and cytokines, including FGF, TGF-β and PDGF ([@B256]). The study suggested enhanced wound closure in treated mice *via* activation of the Rho GTPase signaling pathway, which is involved in cell migration and invasion ([@B134]). Collectively, these findings suggest that ADSCs are a potential therapeutic tool for promoting wound healing.

### Extracellular Vesicles in Wound Healing {#s1_4_2}

Geiger et al. investigated the application of human fibrocyte-derived exosomes in diabetic mice. They found that wound healing was significantly enhanced in all parameters studied ([@B73]). Zhang et al. found human umbilical cord MSC-derived EVs to promote re-epithelialization of a wound model and improved the Wnt4 expression profile ([@B252]). Similarly, Zhang et al. suggested that MSC-derived exosomes promote collagen formation and angiogenesis ([@B253]). ADSC-derived exosome treatment of human dermal fibroblasts seemed to also induce enrichment of the microRNA within the fibroblasts that contribute to healing ([@B33]). In a murine wound model, Wang et al. suggested that IV administration of ADSC-exosome resulted in reduced scar size and altered metalloproteinases that may improve healing ([@B230]). Finally, Ren et al. showed that MVs from ADSCs stimulated proliferation and migration of fibroblasts, keratinocytes, and endothelial cells, particularly *via* the AKT and ERK signaling pathways both *in vitro* and *in vivo* ([@B192]).

### Radiotherapy Soft Tissue Injury {#s1_4_3}

Radiotherapy (RTX) is administered as part of cancer treatment, either before or after surgery or, unusually, in the absence of surgery ([@B198]; [@B204]). The resulting injury may have devastating consequence in terms of chronic tissue fibrosis and breakdown that may expose vital underlying structures; or can cause secondary pain, contracture and functional impairment. ADSCs have been shown to enhance the quality of skin and soft tissues in clinical RTX injury and in animal models. These influences are thought to be mediated in a paracrine fashion by ADSC-secreted elements that counter the chemokine environment generated by the RTX-injury; this includes anti-inflammatory and anti-apoptotic effects ([@B198]; [@B204]).

Haubner et al. investigated the influences of RTX in blood ECs, and showed enhanced gene expression of pro-inflammatory cytokines IL6, FGF, ICAM-1, and VCAM1. This model of co-culture with ADSCs showed restoration of expression profiles of all RTX-altered cytokines ([@B90]). Chang et al. also utilized intra-peritoneal ADSCs after local RTX to show abrogation of inflammation in treatment groups, with restored gastrointestinal tract (GIT) regeneration and enhanced survival ([@B28]). ADSC treatment was also linked with increased serum levels of IL10, VEGFA, bFGF, and EGF; in addition to increased SDF-1-mediated stem cells recruitment to the injured area ([@B28]). Further, Kojima et al. and Lim et al. showed protective influences of ADSC against RTX-induced salivary gland irradiation ([@B127]; [@B97]).

In terms of skin and subcutaneous RTX-induced damage, ADSC treatment resulted in improvement in mouse models of chronic RTX-related impaired wound healing and in unwounded RTX-damaged skin \[marked by altered collagen-based scar index measurements, increased dermal thickening and reduced fibrosis marker Smad-3 ([@B210]; [@B97])\]. A similar study, investigating ADSC-enriched fat grafting in larger animals exposed to RTX, showed labeled ADSC integration into skin and concomitant enhanced wound repair, epithelialization, subcutaneous fat reserves and lower apoptotic rates. In addition, recruitment and activation of lymphoid cells was seen ([@B67]; [@B32]).

### Lymphoedema {#s1_4_4}

Lymphoedema is the chronic swelling of a limb caused by an accumulation of excess interstitial fluid. In time, if unresolved, the fluid accumulation may lead to the formation of excess subcutaneous fibro-adipose tissue ([@B19]). This condition most commonly occurs in a limb and may be the result a developmental malformation that leads to poor interstitial fluid drainage *via* the lymphatic system (primary lymphoedema) ([@B135]). Alternatively, as is the case in most patients, lymphoedema may develop subsequent to a trauma to the lymphatic system. Typically, secondary lymphoedema occurs following surgery or RTX for cancer (in the developed world) or due to filarial infection (in the developing world) that damage lymphatic vessels and impair lymphatic drainage. The pathological features of secondary lymphoedema include inflammation, adipogenesis, and fibrosis.

Shimizu et al. demonstrated the therapeutic potential of ADSCs in lymphangiogenesis by implanting ADSCs into a surgical mouse model of secondary lymphoedema. They showed that ADSCs stimulated lymphangiogenesis by secreting VEGF-C, and enhanced the recruitment of anti-inflammatory M2 macrophages, which were associated with significantly reduced tail swelling in the model ([@B202]). A recent study by Saijo et al. suggested FGF as a novel factor in the ADSC secretome that could potentially contribute to lymphangiogenesis in irradiated human dermal lymphatic endothelial cells (LEC), implying that ADSCs may ameliorate RTX-injury in LECs ([@B200]). Counter to this, however, early lymphangiogenesis has been highlighted as a possible risk factor associated with developing the later stages of lymphoedema in a surgical mouse model of secondary lymphoedema; and, paradoxically, pharmacological inhibition of lymphangiogenesis suppressed lymphedema development in the model ([@B173]). Thus, whether ADSC-mediated lymphangiogenesis could be therapeutically beneficial in lymphoedema remains elusive and requires further investigation.

Mechanistic and small EV-based functional studies by Greening et al. linked key components of cancer cell-derived EVs to the modulation lymphatic vessel formation and metastasis, demonstrating that lymphatics can also be responsive to secretome components ([@B25]). This study demonstrated critical functional effects on lymphangiogenesis mediated by vesicle surface podoplanin (hitherto considered a passive marker of lymphatic endothelial tissue) on small EVs, using a specific neutralizing monoclonal surface-specific antibody. It also highlighted a key role of podoplanin in biogenesis and release of EVs, and in lymphangiogenesis function. However, the role of the ADSC secretome as a driver of lymphatic repair after RTX or other lymphatic injury, remains to be revealed.

### Neurodegenerative Diseases {#s1_4_5}

#### ADSCs in the Treatment of Neurodegenerative Diseases {#s1_4_5_1}

The use of ADSCs has shown promising pre-clinical results in studies investigating several important neurodegenerative disorders, such as Parkinson's disease, Alzheimer's disease, and Huntington's disease. A study using a murine Alzheimer's disease model showed that treatment with human ADSCs significantly enhanced levels of the anti-inflammatory cytokine IL-10, as well as key neurotrophic (and vasculogenic) factors, including VEGF-A - which led to a marked reduction in Aβ plaques and memory impairment, and elevation of endogenous neurogenesis and dendritic stability ([@B124]). Furthermore, autologous implantation of mouse ADSCs in mice with Alzheimer's disease enhanced regeneration of neuroblasts and reduced oxidative stress in the brain, which in turn alleviated cognitive impairment ([@B241]). Exosomes from ADSCs have also been shown to transfer enzymatically active neprilysin, a Aβ-degrading enzyme, *in vitro* ([@B116]). Importantly, this study showed that ADSC exosome-mediated function was more significant than bone marrow derived MSCs, contributing to prevention of extracellular plaque formation, subsequent pathogenesis and a potential Alzheimer's disease therapeutic.

In terms of Parkinson's disease, a common chronic progressive neurodegenerative movement disorder characterized in patients as diminished brain dopamine levels, numerous studies have been performed assessing the therapeutic potential of human ADSCs on a 6-hydroxyldopamine (6-OHDA)-induced mouse Parkinson's disease model ([@B16]). Mitochondrial dysfunction in the brain is known to contribute to pathogenesis of the disease by increasing reactive oxygen species and hence oxidative stress, which exacerbates damage to the dopaminergic neurons in Parkinson's disease ([@B16]). Choi et al. demonstrated that ADSCs significantly improved behavioral performance by decreasing dopaminergic neuronal cell death and the population of damaged mitochondria in the mouse brain; as well as by recovering mitochondrial functions in the brains of ADSC-injected mice ([@B35]). It has also been shown that human ADSCs significantly enhanced expression of brain-derived neurotrophic factor (BDNF) and improved motor lost function in the 6-OHDA murine Parkinson's disease model ([@B15]), suggesting a pro-healing effect. Interestingly, however, the levels of glial fibrillary acidic protein (GFAP), were shown to be up-regulated in the brain of ADSC-treated animals ([@B15]). GFAP is a common indicator of dysfunctional astrocytes, the most abundant central nervous system glial cells. They may contribute to the progression of Parkinson's disease and GFAP upregulation is a possible sign of neuronal regeneration, however, it should be noted that a definitive role for GFAP is not yet agreed upon ([@B15]).

Huntington's disease is a progressive, fatal hereditary neurodegenerative disorder characterized by accumulated mutant *Huntingtin* (mHtt) protein in neural cells, which affects mitochondrial energy metabolism to accelerate cell death by progressive brain atrophy. Therefore, altered mitochondrial energy metabolism due to an impaired CREB-PGC1α pathway is a key risk factor in disease progression, which is characterized by an accumulation of mHtt in the brain ([@B45]; [@B29]). Im et al. investigated the influences of cell-free extracts of human ADSC (ASC-E) on R6/2 mice, which developed Huntington's disease, and found that ASC-E induced activation of the p-CREP-PGC1α pathway and amelioration of mHtt aggregates as well as striatal atrophy in the brain of R6/2 mice ([@B101]). Also, injection of ASC-E in the mouse model slowed progression of the Huntington's disease phenotype, including weight loss and declining rotarod performance; although the molecular contents of the ASC-E that exerted these therapeutic effects was not assessed in this study ([@B101]). Similarly, ADSC implantation in the R6/2 murine Huntington's disease model also showed beneficial effects, such as enhanced rotarod performance, limb clasp and survival; and attenuation of striatal neurons loss; as well as diminished brain aggregation of mHtt ([@B136]). These results were found to be driven by CREB-PGC1α pathway activation ([@B136]). Altogether, these studies suggest that ADSC treatment could constitute a novel treatment tool useful in ameliorating key pathogenic steps in the development of Huntington's and other similar neurodegenerative diseases.

### Exosomes in the Treatment of Neurological Diseases {#s1_4_6}

There have been a few studies demonstrating critical roles of ADSC-exosomes in neuro-protection and neuro-regeneration owing to their capacity to cross the blood-brain barrier ([@B4]). For instance, ADSC-exosomes have been shown to mediate functional neuro-regeneration in stroke. Geng et al. demonstrated in a rodent model that miR-126 enriched ADSC-exosomes enhanced neurogenesis and vasculogenesis after stroke ([@B74]). These results are in keeping with a rat experiment undertaken by Yang and colleagues, in which miR-181b-5p-enriched ADSC-exosomes promoted mobility and angiogenesis of brain microvascular endothelial cells in stroke ([@B242]). The manner in which exosomes transverse the blood-brain barrier by using transcytosis through endothelial cells are capable of mediating astrocytes to degrade the cell cytoskeleton ([@B163]), and have only recently been elucidated. Furthermore, neuroinflammation is a major complication of brain injury, which is triggered by the activation of microglia cells in the central nervous system ([@B55]). miR-126-enriched ADSC-exosomes were shown to significantly inhibit post-stroke inflammation by suppressing activation of microglial cells and reducing pro-inflammatory cytokine levels in the rat brain ([@B74]). Feng et al. also demonstrated ADSC-exosomes to inhibit microglial activation by inhibiting the pro-inflammatory MAPK and NF-κβ signaling pathways, which protected rat brain neural cells from injury ([@B64]).

Potential gene candidates in ADSC-exosomes that underpin these therapeutic effects have been explored using models of neurite outgrowth and sciatic nerve regeneration. Bucan et al. showed rat ADSC-exosomes to contain a range of neurotrophic factors, such as glial-cell derived neurotrophic factor, FGF-1, BDNF, ILGF-1, as well as nerve growth factor (NGF) ([@B20]). Schwann cells are also simulated by neurotrophic factors NGF and BDNF and elicited pro-regenerative effects in nerve regeneration after nerve damage ([@B103]). Chen et al. also demonstrated that exosomes derived from human ADSCs enhanced secretion of BDNF and NGF by Schwann cells, which led to increased proliferation, myelination, migration of cells in a dose-dependent manner *in vitro* ([@B30]). Additionally, this study assessed the effects of ADSC-exosomes on gastrocnemius muscle atrophy (a readout of sciatic nerve injury in rats) and found that treatment with the ADSC-exosome improved muscle atrophy by promoting axonal regeneration and myelination; although exosomal components that exerted these effects remained unidentified ([@B30]). Lastly, another study showed ADSC-exosomes to inhibit apoptosis and increase proliferation of Schwann cells in rats after nerve injury ([@B30]); an additional potential mechanism by which the ADSC-exosomes may promote nerve regeneration.

Several other studies demonstrated beneficial effects of ADSC-exosomes on key neurodegenerative diseases. Lee et al. demonstrated that ADSC-EVs significantly reduced the levels of Aβ plaques in Alzheimer's disease, inhibiting apoptosis of neuronal cells and augmenting neurite outgrowth of neuronal cells *in vitro* ([@B139]). In Huntington's disease ([@B34]), Lee *el al*. showed that Huntington's disease model that ADSC-EVs profoundly decreased mHtt aggregates and inhibited apoptosis of neuronal cells *in vitro*. Mitochondrial dysfunction was attenuated by activation of the proliferator-activated receptor γ coactivator 1α (PGC1α) and cAMB response element binding protein (CREB)-peroxisome pathways ([@B45]; [@B29]; [@B140]). Finally, in Parkinson's disease ([@B159]). Meligy et al. studied a rotenone-induced rat model of Parkinson's disease to demonstrate that ADSC-EVs significantly increased levels dopamine in the treatment group compared to the control ([@B160]). In contrast to the overexpression of GFAP seen in animals treated with ADSCs ([@B37]), it was shown that ADSC-EVs markedly *decreased* the gene expression of GFAP, restored astrocytic injury, and improved motor performance in their Parkinson's disease model ([@B160]). This suggested that GFAP may play a different role in neuroprotection in the same model whether treated with ADSCs or ADSC-EVs. Overall, these results indicated that the ADSC-EVs may have reparative potential in incurable neurodegenerative disorders. Further studies are needed to understand the neuroprotective mechanisms by EVs.

### ADSCs in Renal Diseases {#s1_4_7}

AKI is a complex clinical condition characterized by deteriorating renal function due to decreased renal perfusion, blood supply and glomerular filtration rates, caused by damage to nephron structures ([@B183]; [@B176]). AKI may progress to long-term chronic kidney disease (CKD), for which there is currently no cure ([@B184]). Thus, prevention of transition of AKI to CKD is critical. Implantation of ADSCs has been shown to yield beneficial effects on rat models of acute kidney injury (AKI). For example, ADSC treatment in an ischemia/reperfusion (I/R)-induced rat model of AKI significantly decreased the number of apoptotic kidney cells and effectively restored urine protein and serum creatinine levels ([@B254]). This finding suggested restoration of kidney function by ADSC treatment, and was consistent with the findings by Lin et al. ([@B145]). Moreover, ADSC treatment lead to markedly reduced expression levels of multiple pro-inflammatory cytokines, for example, IL-6, TNF-α, and IFN-γ; however, was associated with elevated expression of anti-inflammatory cytokine, IL-10 ([@B254]) at the mRNA level. Furthermore, ADSC treatment effectively ameliorated diabetic nephropathy by reducing oxidative stress and inflammatory cytokines levels (e.g. IL-6 and TNF-α), by mediating the inhibition of the pro-inflammatory p38 MAPK signaling pathway ([@B62]), a factor involved in the development of human diabetic nephropathy ([@B1]).

### Extracellular Vesicles and Renal Disease {#s1_4_8}

ADSC-EVs have been demonstrated to have a pivotal role in protection from the development of AKI. Zhu et al. studied downstream effects of using ADSC-EVs to prevent transition of AKI to CKD, in a mouse model of renal I/R injury. The authors showed that mice treated with ADSC-EVs exhibited decreased renal I/R injury and increased proliferation of renal tubular epithelial cells, thus attenuating AKI ([@B259]). Notably, treatment with ADSC-EVs resulted in upregulation of tubular SOX9 gene expression ([@B259]), a key gene involved in renal repair and renal tubule epithelial cell regeneration ([@B130]; [@B112]). Furthermore, reduced levels of the pro-fibrotic cytokine TGF- β1 were observed following the ADSC-EV treatment in the model, suggesting that the EVs inhibited TGF-β1-induced renal fibrosis ([@B259]), a key feature of CKD ([@B98]). Another study by Lin et al. demonstrated that inflammation, oxidative stress, apoptosis, fibrosis, and glomerular and renal tubular damage were mitigated by a combined treatment of ADSC-EVs and ADSCs in a rat model of renal I/R injury ([@B145]).

In diabetic nephropathy, a common variety of CKD due to impaired podocyte autophagy resulting from aberrant activation of the mTOR signaling pathway, a more recent study employed a spontaneous diabetic mouse model to assess the roles of ADSC-EVs ([@B78]; [@B212]). It was demonstrated that serum creatinine and blood urea nitrogen and total urinary protein levels, indicators of renal dysfunction, were significantly reduced by ADSC-EVs in diabetic mice ([@B109]). This finding correlated with the study in AKI carried out by Lin et al. ([@B145]). Additionally, ADSC-EVs were shown to enhance autophagy (the body's clearance of cellular debris) and diminish podocyte apoptosis by restricting Smad1/mTOR pathway activation *via* miR-486 ([@B109]). Activation of miR-486 is important as expression of miR-486 has been found to be down-regulated in diabetic patients when compared with non-diabetic individuals ([@B189]), implying that miR-486-enriched ADSC-EVs could be a potential therapeutic for treating diabetic nephropathy. Overall, these findings suggest a therapeutic use for ADSCs in kidney diseases such as AKI and diabetic nephropathy, given their capacity to suppress oxidative stress and inflammation; and the possible additional future efficacy of ADSC-EV in AKI.

### ADSCs in Cancer {#s1_4_9}

A study using a xenograft mouse model of human breast cancer showed that human ADSCs promoted tumor growth when injected *into* a tumor. In contrast, ADSCs inhibited tumor growth when injected *around* the tumor ([@B100]), suggesting distinct influences of ADSCs in different tumor microenvironments. A recent study by Xu et al. showed that ADSCs could promote metastases in mice xenografted with breast carcinoma through ADSC-released stem cell factor-mediated inhibition of miR20b, which in turn, lead to activation of the c-Kit/MAPK-p38/E2F1 signaling pathway and increased expression of HIF-1α and VEGFA ([@B239]). Meanwhile, upregulation of miR20b reduced metastasis of 4T1 breast cancer cells to the lung, suggesting that miR20b acted as a tumor suppressor miRNA, and that ADSCs may be able to induce lung metastases *in vivo*, through miR-20b inhibition ([@B239]). In contrast, miR-20b was also shown to enhance breast cancer proliferation both *in vitro* and *in vivo* by inhibiting expression of the phosphatase and tensin homologue (PTEN) gene ([@B257]), a well-known tumor suppressor gene involved in regulation of breast cancer cells ([@B50]). This discrepancy may be due to heterogenous roles of miR-20b in regulating breast cancer development in the presence of ADSCs and the ADSC secretome; or may be due to poor study design. Hence, before conclusions can be drawn, this area warrants further detailed studies. Controversies regarding the regulatory approval for use of fat grafting in a former or current tumor bed are summarized above and in ([@B50]).

### ADSC-Derived Extracellular Vesicles in Cancer {#s1_4_10}

Given the capacity of EVs to exert their effects by transferring proteins and RNA to target cells, the effects of EVs in promoting cancer progression has been studied extensively \[reviewed in ([@B237])\]. It appears that ADSC-EVs have dual (or contradictory) functions in regulating tumorigenesis, both by promoting and inhibiting the growth of cancer cells. For instance, platelet-derived growth factors stimulate ADSCs to release EVs containing pro-angiogenic factors---such as Axl ([@B214]), artemin ([@B12]) and stem cell factor ([@B250])---which have been shown to enhance angiogenesis in human microvascular endothelial cells ([@B148]). An *in vitro* study demonstrated that ADSC-EVs promoted migration and proliferation of MCF7 human breast carcinoma cells through activation of Wnt/β-catenin signaling ([@B144]), although the involvement of angiogenesis was not assessed.

In contrast, there have been a few studies demonstrating that ADSC-EVs can act as tumor suppressors. For example, Takahara et al. demonstrated notable reduction in prostate cancer growth in tumor-bearing mice following ADSC-EVs treatment, an effect mediated *via* activation of the caspase-3/7 pro-apoptotic pathway, itself signaling *via* miR-145 ([@B213]). The therapeutic potentials of microRNA-enriched EVs have also been explored in several tumor models. For example, miR-122 is highly expressed in the liver, and loss of miR-122 correlated with development of hepatocellular carcinoma (HCC) in mice ([@B224]). Lou et al. demonstrated that miR-122 transfected ADSC-secreted EVs were rich in miR-122, and that uptake of these EVs by cultured HCC cells lead to increased chemosensitivity to chemotherapeutic agents and significant reduction in tumor growth *in vivo* ([@B149]). Similar results were shown in a breast cancer study ([@B172]) employing ADSC-EVs enriched with miR-379, a tumor suppressor miRNA whose expression is down-regulated in breast cancer ([@B118]). It was found that the miR-379-enriched ADSC-EVs significantly inhibited tumor growth without adverse effects in mice over the 6 weeks of monitoring ([@B172]). These findings suggested a potential application of genetically engineered ADSCs to promote secretion of EVs encapsulated in tumor suppressor miRNAs may be a promising, novel strategy to treat cancer. However, whether ADSC-EVs have long-term therapeutic effects after withdrawal of administration is unknown.

### Extracellular Vesicles in Cardiac Disease---Pathology and Cardio-Protection {#s1_4_11}

EVs derived from human ADSCs have been shown to demonstrate cardioprotective roles through their paracrine effects rather than the direct differentiation into cardiomyocytes. Cui et al. used a rodent myocardial I/R injury model to show that ADSC-EVs protected the myocardium from ischemia- or hypoxia- induced necrosis and apoptosis ([@B46]). Implantation of ADSC-EVs in the rat model resulted in significant reduction in the levels of apoptotic proteins detected (e.g. Bax), and a significant increase in the expression of pro-survival proteins, including Bcl-2 and Cyclin D1 in rat myocardium ([@B46]). Further, ADSC-EVs exerted cardioprotective effects *via* activation of Wnt/β-catenin signaling ([@B46]). Another experiment investigating treatment of a rodent model of myocardial infarction with ADSC-EVs profoundly improved cardiac dysfunction by suppressing cardiac apoptosis and fibrosis ([@B52]). Interestingly, ADSC-EVs promoted macrophage M2 polarization by activating the sphingosine 1-phosphate/sphingosine kinase 1/sphingosine-1-phosphate receptor 1 signaling pathway, which inhibited inflammatory responses and reduced myocardial fibrosis, suggesting that ADSC-EVs may exert potential anti-inflammatory effects ([@B52]). In addition, Luo et al. employed genetically modified ADSCs to overexpress miR-126 (a microRNA shown to exhibit cardioprotective effects in myocardial infarction) in EVs ([@B147]; [@B63]). The miR-126-enriched ADSC-EVs significantly decreased myocardial injury by inhibiting inflammation and fibrosis, and enhancing microvascular generation and migration in rats ([@B152]). Limitations of ADSC treatments for ischemia heart disease include low cardiac retention rates and insufficient concentrations and retained volumes ([@B142]). Numerous clinical trials of ADSCs-derived products have shown promise and an account of completed and ongoing clinical trials using ADSCs are summarized in [**Table 3**](#T3){ref-type="table"}.

###### 

Completed and ongoing clinical trials of ADSCs.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Diseases                                                  Study phase   Intervention or treatment                      Autologous/Heterologous/Allogeneic                 Key findings ADSC/EVs                                                        Reference
  --------------------------------------------------------- ------------- ---------------------------------------------- -------------------------------------------------- ---------------------------------------------------------------------------- -------------
  Fingertip injury                                          Pilot study   Injections at the site of injury               Autologous                                         Accelerate wound healing process and recovery of sensory function            ([@B215])

  Idiopathic pulmonary fibrosis                             Ib            Intravenous injections of ADSC-derived SVF     Autologous                                         Similar survival rates disease progression time in untreated populations.\   ([@B171])
                                                                                                                                                                            Fail to demonstrate any beneficial effect by ADSC therapy                    

  Refractory Perianal fistula in Crohn's disease            III           Local injections of allogenic expanded ADSCs   Autologous                                         Remission of fistula openings and reduce perianal disease (MRI)              ([@B179])

  Secondary progressive multiple sclerosis                  I/II          Intravenous injections                         Autologous                                         Safe & feasible in patients. No significant changes in safety parameters     ([@B65])

  osteoarthritis                                            I/IIa         Intra-articular injections                     Autologous                                         Safe and improved pain, function and cartilage volume of knee joint          ([@B206])

  Diseases                                                                Study phase                                    Intervention or treatment                          Autologous/Heterologous/Allogeneic                                           NCT number

  Chronic kidney diseases                                                 I/II                                           Intravenous injection                              Autologous                                                                   NCT03939741

  Diabetic foot ulcer                                                     I/II                                           ADSC-enriched fibrin gel                           Autologous                                                                   NCT03865394

  Chronic obstructive pulmonary disease                                   I                                              Intravenous injection                              Autologous                                                                   NCT02161744

  Isolated Articular Cartilage Defects                                    Unknown                                        ADSC-enriched acellular dermal matrix              Autologous                                                                   NCT02090140

  Moderate to Severe Chronic Kidney Disease                               I/II                                           Allogenic injection                                Allogeneic                                                                   NCT02933827

  Knee Osteoarthritis                                                     I/II                                           Intra-articular injection                          Allogenic                                                                    NCT02784964

  Scars or cutis laxa                                                     I/II                                           Autologous injection combined with laser therapy   Autologous                                                                   NCT03887208

  Stroke                                                                  I                                              Intravenous injection                              Unknown                                                                      NCT03570450

  Knee osteoarthritis                                                     III                                            Intra-articular injection                          Autologous                                                                   NCT03467919

  Knee osteoarthritis                                                     Unknown                                        Transplantation                                    Autologous                                                                   NCT03014401

  Vestibulodynia                                                          Unknown                                        Transplantation                                    Unknown                                                                      NCT03431779

  Alopecia                                                                Unknown                                        Transplantation                                    Unknown                                                                      NCT03427905

  Ischemic Heart Disease and Left Ventricular Dysfunction                 I                                              ADSC-enriched VB-C01 collagen patches              Allogeneic                                                                   NCT03746938

  Facial Rejuvenation                                                     Unknown                                        Intradermal injection                              Autologous                                                                   NCT03928444
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### Summary of ADSC-Derived Clinical Trials {#s1_4_12}

The focus of this review is pre-clinical data supporting ADSC-derived therapy; however, it is worth noting that several early clinical trials have been completed. Studies using non-adipose sourced stem cells are not discussed. Trials conducted to assess the benefit of ADSC-derived treatment of wounds, have only reached pilot study or phase I stage in simple cutaneous wounds ([@B122]; [@B92]); however, in Crohn's disease-related peri-anal fistulae, a phase III study ([@B178]) has shown good efficacy. Similarly, good efficacy has been shown in phase I and IIa studies involving treatment of osteoarthritis ([@B206]) and phase III studies are ongoing at the time of writing ([**Table 3**](#T3){ref-type="table"}). Finally, promise has also been shown in central nervous system disease \[phase I and II studies in multiple sclerosis ([@B65])\].

The dynamic nature of the field warrants close observation of the ongoing results of these clinical studies. It is hoped, however, that the application of genetically modified ADSC-derived small EVs may overcome issues encountered in trials of ADSCs and enhance our capacity to tailor and target future treatment approaches.

Conclusion {#s2}
==========

Fat has played a critical role in basic survival and function throughout the history of human evolution. Now, through evolving the role of fat, humankind may unlock critical answers that assist in novel therapeutic approaches to age-old human diseases; as well as those brought upon ourselves by the evolution of the modern lifestyle. The humble, and until recently rather unfashionable, fat cell may hold the secrets to combatting these diseases---be it through old-fashioned "en-bloc" delivery as raw fat graft, through more sophisticated ADSC-enrichment or cutting-edge discovery and harnessing of paracrine factors in exosomes and other EV types as depicted in [**Figure 2**](#f2){ref-type="fig"}. Together, these insights and the putative treatment that result, may themselves form the cornerstone of the future treatment approaches in regenerative medicine.

![Fat therapeutics of adipose tissue in human disease. Schematic summary of adipose tissue "fat graft" obtained *via* liposuction of subcutaneous fat. Refinement of this fat graft can has occurred at various levels from the acquisition of the rudimentary fat graft, further processed with digestion to obtain the stromal vascular fraction cell pellet, further refinement with extraction of ADSCs, and extracellular vesicle isolation (left column). Each of these components demonstrate significant therapeutic potential in reversing the pathology of human disease, across a range of body systems (middle column). The mechanisms by which these effects are mediated are illustrated in the right-hand column. Figure adapted from Shukla et al. (2015) under the CC-BY license ([@B204]).](fphar-11-00158-g002){#f2}
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